Cosmos Holdings

Cosmos Health, Inc. is a pharmaceutical company, which engages in the importation, exportation, distribution, and sale of pharmaceutical products. It is also involved in the research and development of its business units, and acquisition of pharmaceutical companies. The firm offers over-the-counter drugs, branded and generic medicines, and dietary and vitamin supplements. The company was founded on July 21, 2009 and is headquartered in Chicago, IL.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q2 2024

Earnings data Q1 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cosmos Health, Inc. is a pharmaceutical company, which engages in the importation, exportation, distribution, and sale of pharmaceutical products. It is also involved in the research and development of its business units, and acquisition of pharmaceutical companies. The firm offers over-the-counter drugs, branded and generic medicines, and dietary and vitamin supplements. The company was founded on July 21, 2009 and is headquartered in Thessaloniki, Greece.

CHICAGO, IL / ACCESSWIRE / September 27, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today its intention to spin off its research and development (R&D) division into a publicly listed standalone biotech company. Cosmos Health has been investing in innovative R&D over the past few years.

Cosmos Health Actively Exploring Spinoff of R&D Division into a Publicly Listed Standalone Biotech Company

CHICAGO, IL / ACCESSWIRE / September 26, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the expansion of its C-Sept brand with the launch of the new C-Scrub Wash 4% CHG Biocide. Following the acquisition of Cana Laboratories ("Cana"), Cosmos Health obtained a proprietary portfolio of branded pharmaceutical, dermocosmetic, antiseptic, and food supplement products, including the C-Sept brand.

Cosmos Health Announces Expansion of Its C-Sept Brand with the Launch of C-Scrub Wash; Capitalizing on $29 Billion Global Antiseptic and Disinfectant Market

CHICAGO, IL / ACCESSWIRE / September 22, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the relaunch of its organic infant care and nutrition brand, bio-bebe®. On July 6, 2023, Cosmos Health announced that it had successfully completed the acquisition of Cana Laboratories ("Cana").

Cosmos Health Announces Relaunch of bio-bebe, its Proprietary Organic Infant Care & Nutrition Brand; Aims to Penetrate $103bn Global Baby Food Market

CHICAGO, IL / ACCESSWIRE / September 20, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into a strategic collaboration with C.A.PAPAELLINAS Group. The decision was taken in light of the successful initial agreement between Cosmos Health and Holland & Barrett, one of the world's leading health and wellness retailers and the largest in Europe, which is operated exclusively by C.A.PAPAELLINAS Group in Cyprus.

Cosmos Health Announces Strategic Collaboration with C.A.PAPAELLINAS Group

CHICAGO, IL / ACCESSWIRE / September 13, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the start of the Company's stock buyback program. The Company is committed to taking all available measures to enhance shareholder value.

Cosmos Health Starts Stock Buyback Program

Company reaches major strategic inflection point, with operations and revenue ramp-up underway Inaugural 2026 guidance introduced; target to achieve: More than $180 million in gross annual revenue EBITDA in excess of $20 million So far in 2023, among other achievements: Completed three acquisitions Made notable progress in R&D Nutraceutical brands "Sky Premium Life" and "Mediterranation" experiencing significant market success, expanding into new sales channels and geographies Maintains a robust balance sheet with negligible debt and a strong, diversified asset base Actively exploring initiatives to enhance shareholder value CHICAGO, IL / ACCESSWIRE / September 12, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today announced its inaugural 2026 revenue and EBITDA guidance and released a recap of the Company's significant activities and events reported so far in 2023. Greg Siokas, Chief Executive Officer of Cosmos Health, stated: "We are pleased to announce guidance based on our long-term outlook to achieve substantial growth and profitability.

Cosmos Health Introduces Guidance; Expects to Achieve Over $180M in Gross Annual Revenue and EBITDA in Excess of $20M by 2026; Recaps Significant Events Reported So Far in 2023

CHICAGO, IL / ACCESSWIRE / August 15, 2023 / Cosmos Health Inc. ("Cosmos Health" or "the Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported its financial results for the second quarter of 2023. Q2 and H1 2023 Financial Highlights Revenues amounted to $12.36 million in Q2 2023 and $24.71 million in H1 2023, a slight decline of 6.4% and 5.96%, respectively, from $13.21 million and $26.28 million in the corresponding periods in 2022, in part due to unfavorable USD to EUR and GBP exchange rate movements.

Cosmos Health Reports Q2 2023 Financial Results; Adjusted Net Income Increases by 3550% to Surpass $3 Million for H1 2023 vs $(0.09) Million H1 2022; Book Value per Share Exceeds $4.04

CHICAGO, IL / ACCESSWIRE / August 8, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today the engagement of KPMG Certified Auditors S.A. ("KPMG") as the Company's independent registered public accounting firm, effective August 7, 2023.

Cosmos Health Appoints Big 4 Accounting Firm KPMG as Auditor

CHICAGO, IL / ACCESSWIRE / August 2, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today the launch of Eleonas and Olympus Mons, the latest additions to its Mediterranation line of products, and is in the process of ramping up its export growth and sales, after having secured several purchase orders, including from a leading multinational health food chain. Mediterranation is the Company's premium nutritional supplements brand that draws inspiration from the Mediterranean way of life.

Cosmos Health Continues to Expand Mediterranation Brand, Welcomes Eleonas and Olympus Mons; Boosts Exports and Secures Purchase Orders, Including from Leading Multinational Health Food Chain

Brainstorm Cell Therapeutics

Protagonist Therapeutics

Sharecare

Beyond Air Inc

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Quarter

CHICAGO, IL / ACCESSWIRE / July 25, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today provided an update on recent developments, reaffirming the management team's belief and commitment to future prospects, and highlighting CEO Greg Siokas' participation in all capital raises since inception. The Company maintains a robust balance sheet with negligible debt and a strong, diversified asset base, including tangible assets such as unencumbered freehold properties as well as machinery and equipment with a fair market value in excess of $12 million.

Cosmos Health Provides Update on Recent Developments, Maintains Strong Financial Position, Reaffirms Commitment to Growth, and Highlights CEO's Continued Investment Now Exceeds $15 Million

CHICAGO, IL / ACCESSWIRE / July 21, 2023 / Cosmos Health Inc. (the "Company") (Nasdaq:COSM) , a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced the closing of its previously announced offering of 2,116,936 shares of the Company's common stock (or common stock equivalents in lieu thereof) in a registered direct offering and common warrants to purchase up to 1,935,484 shares of common stock in a concurrent private placement (together with the registered direct offering, the "offering"). The combined purchase price for one share of common stock (or common stock equivalent) and one common warrant was $2.48.

Cosmos Health Inc. Announces Closing of $5.25 Million Registered Direct Offering and Concurrent Private Placement

CHICAGO, IL / ACCESSWIRE / July 20, 2023 / Cosmos Health Inc. (the "Company") (NASDAQ:COSM) , a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced that it has entered into securities purchase agreements with institutional investors for the purchase and sale of 2,116,936 shares of the Company's common stock (or common stock equivalents in lieu thereof) in a registered direct offering and common warrants to purchase up to 1,935,484 shares of common stock in a concurrent private placement (together with the registered direct offering, the "offering"). The combined purchase price for one share of common stock (or common stock equivalent) and one common warrant will be $2.48.

Cosmos Health Inc. Announces Pricing of $5.25 Million Registered Direct Offering and Concurrent Private Placement

CHICAGO, IL / ACCESSWIRE / July 6, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today the successful closing of the acquisition of Pharmaceutical Laboratories CANA S.A., ("Cana"), a Greek pharmaceutical company that manufactures, sells, distributes, and markets original branded products researched and developed by leading global pharmaceutical and healthcare companies.

Cosmos Health Successfully Completes Acquisition of Cana Laboratories; Anticipates to Record a Substantial Gain on Bargain Purchase

CHICAGO, IL / ACCESSWIRE / June 29, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today the launch of Chios Island, the latest addition to the Mediterranation line of products. Mediterranation is the Company's premium nutritional supplements line that draws inspiration from the Mediterranean way of life.

Cosmos Health Launches Chios Island, the Latest Addition to Its Mediterranation Premium Line of Supplements

CHICAGO, IL / ACCESSWIRE / June 21, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today the successful completion of the second phase in the development of the CCX0722 product and its extensions, an innovative solution for obesity and weight management. The Company believes that this represents a significant advancement in the fight against obesity and metabolic syndrome, offering a multifunctional mechanism of action.

Cosmos Health Successfully Completes Second Phase of CCX0722 Development, an Innovative Product for Obesity and Weight Management: Significant Step in Bringing Product to the Multi-Billion-Dollar Market

CHICAGO, IL / ACCESSWIRE / June 16, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today the successful closing of the acquisition of the distribution network owned by I.Bikas General Partnership ("Bikas"), an established pharmaceutical company that has been operating in Greece since 1986. This strategic bolt-on transaction, through inclusion into the distribution network operated by the Company's wholly-owned subsidiary CosmoFarm Pharmaceuticals S.A.

Cosmos Health Successfully Closes Acquisition of Assets from I. Bikas GP; Annual Revenue Projected to Grow by over $10 Million

CHICAGO, IL / ACCESSWIRE / June 13, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today the launch of Terra Creta, the latest addition to the Mediterranation line of products. Mediterranation is the Company's premium nutritional supplements line that incorporates organic herbs and plant extracts such as crataegus, hibiscus, dittany of Crete, oregano, mastic, and kritamos from Greece and the Mediterranean, comprising exclusive formulations of vitamins and minerals crafted with high-quality raw materials, manufactured under strict pharmaceutical standards and good manufacturing practices (GMP) protocols.

Cosmos Health Expands Premium Nutritional Supplements Line Mediterranation with the Launch of Terra Creta

CHICAGO, IL / ACCESSWIRE / May 31, 2023 / Cosmos Health Inc. ("Cosmos Health" or "the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today that it is set to join the Russell Microcap® Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens on June 26, according to a preliminary list of additions posted May 19. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes.

Cosmos Health set to join Russell Microcap Index

CHICAGO, IL / ACCESSWIRE / May 25, 2023 / Cosmos Health Inc. ("Cosmos Health" or "the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today that it has executed a binding Letter of Intent (LOI) to acquire all of the outstanding shares of Docpharm GmbH. ("Docpharm"), an established pharmaceutical distributor based in Germany.

Cosmos Health Enters into Binding Letter of Intent for the Acquisition of Docpharm GmbH., an Established German Pharmaceutical Distributor; Expected to Boost Our Annual Revenue by Approximately €32M, or 70%, by the End of 2025 vs FY 2022.

CHICAGO, IL / ACCESSWIRE / May 17, 2023 / Cosmos Health Inc. ("Cosmos Health" or "the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today provided a business update and reported financial results for the first quarter ended March 31, 2023. First Quarter 2023 Financial Highlights Revenues amounted to $12.35 million, compared to $13.07 million in Q1 2022.

Cosmos Health Reports First Quarter 2023 Financial Results; Delivers Positive Adjusted EBITDA and Significant Increase in Adjusted Net Income

CHICAGO, IL / ACCESSWIRE / May 8, 2023 / Cosmos Health Inc. ("Cosmos Health" or "the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today that it has executed a Stock Purchase Agreement ("SPA") for, and has now entered the final phase for the acquisition of, Pharmaceutical Laboratories CANA S.A., ("Cana"), a Greek pharmaceutical company that manufactures, sells, distributes, and markets original branded products researched and developed by leading global pharmaceutical and healthcare companies.

Cosmos Health Enters Final Phase for the Acquisition of Cana Laboratories Following Conclusion of Stock Purchase Agreement

CHICAGO, IL / ACCESSWIRE / May 3, 2023 / Cosmos Health Inc. ("Cosmos Health" or "the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced that is has acquired the entire property which houses the operations of its wholly owned subsidiary CosmoFarm Pharmaceuticals ("CosmoFarm"), a fully licensed pharmaceutical wholesale company operating in the western part of Athens, Greece. The CosmoFarm property, pictured below, comprises an entire 3-story building, 2,700 square meters (or approximately 29,063 square feet) in size.

Cosmos Health Advances Its Strategic Plan; Acquires Distressed Property Housing Operations of CosmoFarm, Expected to Generate Substantial Value for Shareholders

Evolv Technologies Holdings

ImmunoGen

Terran Orbital Corp

Terawulf

5 penny stocks to watch. The post 5 Hot Penny Stocks To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Hot Penny Stocks To Watch Before Next Week

CHICAGO, IL / ACCESSWIRE / April 13, 2023 / Cosmos Health Inc. ("Cosmos Health" or "the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today provided a business update and reported financial results for the fiscal year ended December 31, 2022. Fiscal Year 2022 Financial Highlights Revenues were $50.3 million versus $56.2 million in FY2021 with the decline being largely due to the high variation in FX differences between EUR and GBP to USD.

News for Cosmos Holdings Stock (COSM)